Доказательная фармакология миоинозитола

человека, играющий значимую роль в жизнедеятельности клеток и тканей. Ключевой ролью миоинозитола и его производных являются передача сигнала внутри клетки и регуляция функции таких важных рецепторов, как рецепторы инсулина, катехоламинов, нейромедиаторов и др. Миоинозитол – вещество, необходимое для синтеза главной группы сигнальных молекул, инозитолфосфатов, которые регулируют передачу сигнала от рецепторов ростовых факторов и нейротрансмиттеров. Большое количество инозитолзависимых белков очень важны для работы сердечно-сосудистой, иммунной систем, для структуры соединительной ткани. Изучены нейротрофические и нейропротекторные эффекты миоинози тола, его роль в обмене сахаров и функционировании почек и печени. Применение миоинозитола позволяет профилактировать развитие фолатрезистентных пороков и способствует нейропротективному действию мозга в условиях стресса.

1. Dinicola S., Minini M., Unfer V. et al. Nutritional and acquired deficiencies in inositol bioavailability. correlations with metabolic disorders. Int J Mol Sci 2017;18(10):2187. DOI: 10.3390/ijms18102187

2. Wong Y.H., Kalmbach S.J., Hartman B.K., Sherman W.R. Immunohistochemical staining and enzyme activity measurements show myo-inositol-1-phosphate synthase to be localized in the vasculature of brain. J Neurochem 1987;48(5):1434–42. DOI: 10.1111/j.1471-4159.1987.tb05682.x

3. Loewus M.W., Loewus F.A., Brillinger G.U. et al. Stereochemistry of the myo-inositol-1-phosphate synthase reaction. J Biol Chem 1980;255(24):11710–2. PMID: 7002927

4. Kwon H.M., Yamauchi A., Uchida S. et al. Cloning of the cDNa for a Na+/myo-inositol cotransporter, a hypertonicity stress protein. J Biol Chem 1992;267(9):6297–301. PMID: 1372904

5. Hitomi K., Tsukagoshi N. cDNA sequence for rkST1, a novel member of the sodium ion-dependent glucose cotransporter family. Biochim Biophys Acta 1994;1190(2):469–72. DOI: 10.1016/0005-2736(94)90110-4

6. Garzon S., Laganà A.S., Monastra G. Risk of reduced intestinal absorption of myo-inositol caused by D-chiro-inositol or by glucose transporter inhibitors. Expert Opin Drug Metab Toxicol 2019;15(9):697–703. DOI: 10.1080/17425255.2019.1651839

7. Berry G.T., Mallee J.J., Kwon H.M. et al. The human osmoregulatory Na+/myo-inositol cotransporter gene (SLC5A3): molecular cloning and localization to chromosome 21. Genomics 1995;25(2):507–13. DOI: 10.1016/0888-7543(95)80052-n

8. Miyakawa H., Woo S.K., Dahl S.C. et al. Tonicity-responsive enhancer binding protein, a rel-like protein that stimulates transcription in response to hypertonicity. Proc Natl Acad Sci USA 1999;96(5):2538–42. DOI: 10.1073/pnas.96.5.2538

9. Majunder A., Biswas B. (Eds.) Biology of inositols and phosphoinositides. Subcellular Biochemistry. Springer: New York, NY, USA, 2006.

10. Лиманова О.А., Громова О.А., Торшин И.Ю. и др. Систематический анализ молекулярно-физиологических эффектов миоинозитола: данные молекулярной биологии, экспериментальной и клинической медицины. Эффективная фармакотерапия 2013;28:32–41.

11. Larner J. D-chiroinositol – its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res 2002;3(1):47–60. DOI: 10.1080/15604280212528

12. Rapiejko P.J., Northup J.K., Evans T. et al. G-proteins of fat-cells. Role in hormonal regulation of intracellular inositol 1,4,5-trisphosphate. Biochem J 1986;240(1):35–40. DOI: 10.1042/bj2400035

13. Clements R.S. Jr, Darnell B. Myoinositol content of common foods: development of a high-myoinositol diet. Am J Clin Nutr 1980;33(9):1954–67. DOI: 10.1093/ajcn/33.9.1954

14. Hurrell R.F. Influence of vegetable protein sources on trace element and mineral bioavailability. J Nutr 2003;133(9):2973S–7S. DOI: 10.1093/jn/133.9.2973S

15. Торшин И.Ю., Громова О.А., Тетруашвили Н.К. Хемотранскриптомный анализ синергизма D-хироинозитола и миоинозитола в контексте постгеномной фармакологии. Акушерство и гинекология 2022;9:135–45. DOI: 10.18565/aig.2022.9.135-145

16. Bevilacqua A., Bizzarri M. Inositols in insulin signaling and glucose metabolism. Int J Endocrinol 2018;2018:1968450. DOI: 10.1155/2018/1968450

17. Hong J.H., Jang H.W., Kang Y.E. et al. Urinary chiro- and myoinositol levels as a biological marker for type 2 diabetes mellitus. Dis Markers 2012;33(4):193–9. DOI: 10.3233/DMA-2012-0925

18. Hacibekiroğlu M., Akçay T. The role of plasma, erythrocyte and platelet myo-inositol levels in the development of diabetic microangiopathy. Diabetes Res 1994;25(4):173–9. PMID: 7648788

19. Corrado F., D’Anna R., Di Vieste G. et al. The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes. Diabet Med 2011;28(8):972–5. DOI: 10.1111/j.1464-5491.2011.03284.x

20. Доброхотова Ю.Э., Громова О.А., Духанин А.С. и др. Инозитолы: фармакология и данные клинических исследований. Современное состояние вопроса и перспективы. РМЖ. Мать и дитя 2022;5(4):309–19. DOI: 10.32364/2618-8430-2022-5-4-309-319

21. Melmed S., Lewin L.M., Bank H. Myoinositol clearance in renal failure and in patients with normal kidney function. Am J Med Sci 1977;274(1):55–9. DOI: 10.1097/00000441-197707000-00007

22. Rysz J., Bartnicki P., Błaszczak R. et al. Przeciwzapalnedziałaniemi oinozytolu w przewlekłejniewydolnościnerek [Anti-inflammatory action of myoinositol in renal insufficiency]. Pol Merkur Lekarski 2006;20(116):180–3. (Polish.). PMID: 16708635

23. Han W., Gills J.J., Memmott R.M. et al. The chemopreventive agent myoinositol inhibits Akt and extracellular signal-regulated kinase in bronchial lesions from heavy smokers. Cancer Prev Res (Phila) 2009;2(4):370–6. DOI: 10.1158/1940-6207.CAPR-08-0209

24. Fernando K.T., McLean M.A., Chard D.T. et al. Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis. Brain 2004;127(Pt 6):1361–9. DOI: 10.1093/brain/awh153

25. Young G.B., Hader W.J., Hiscock M. et al. The role of myo-inositol in multiple sclerosis. J Neurol Neurosurg Psychiatry 1986;49(3):265–72. DOI: 10.1136/jnnp.49.3.265

26. Walecki J., Barcikowska M., Ćwikła J.B., Gabryelewicz T. N-acetylaspartate, choline, myoinositol, glutamine and glutamate (glx) concentration changes in proton MR spectroscopy (1H MRS) in patients with mild cognitive impairment (MCI). Med Sci Monit 2011;17(12):MT105–11. DOI: 10.12659/msm.882112

27. Coupland N.J., Ogilvie C.J., Hegadoren K.M. et al. Decreased prefrontal Myo-inositol in major depressive disorder. Biol Psychiatry 2005;57(12):1526–34. DOI: 10.1016/j.biopsych.2005.02.027

28. Holub B.J. Metabolism and function of myo-inositol and inositol phospholipids. Annu Rev Nutr 1986;6:563–97. DOI: 10.1146/annurev.nu.06.070186.003023

29. Zhu X., Schuff N., Kornak J. et al. Effects of Alzheimer disease on fronto-parietal brain N-acetyl aspartate and myo-inositol using magnetic resonance spectroscopic imaging. Alzheimer Dis Assoc Disord 2006;20(2):77–85. DOI: 10.1097/01.wad.0000213809.12553.fc

30. Kallenberg K., Bock H.C., Helms G. et al. Untreated glioblastoma multiforme: increased myo-inositol and glutamine levels in the contralateral cerebral hemisphere at proton MR spectroscopy. Radiology 2009;253(3):805–12. DOI: 10.1148/radiol.2533071654

31. Siger M., Schuff N., Zhu X. et al. Regional myo-inositol concentration in mild cognitive impairment Using 1H magnetic resonance spectroscopic imaging. Alzheimer Dis Assoc Disord 2009;23(1):57–62. DOI: 10.1097/WAD.0b013e3181875434

32. Herman-Sucharska I., Grzybek M., Grochowska A. et al. Ocenazachowaniamioinozytolu w widmiemetabolicznymmózgowia (HMRS) u pacjentów z encefalopatiawatrobowa [Myoinositol trends in HMRS brain spectrum of patients with hepatic encephalopathy]. Przegl Lek 2010;67(4):247–50. (Polish.). PMID: 20687354

33. Haroon E., Watari K., Thomas A. et al. Prefrontal myo-inositol concentration and visuospatial functioning among diabetic depressed patients. Psychiatry Res 2009;171(1):10–9. DOI: 10.1016/j.pscychresns.2008.03.006

34. Wellard R.M., Briellmann R.S., Prichard J.W. et al. Myoinositol abnormalities in temporal lobe epilepsy. Epilepsia 2003;44(6):815–21. DOI: 10.1046/j.1528-1157.2003.44102.x

35. Willmroth F., Drieling T., Lamla U. et al. Sodium-myo-inositol co-transporter (SMIT-1) mRNA is increased in neutrophils of patients with bipolar 1 disorder and down-regulated under treatment with mood stabilizers. Int J Neuropsychopharmacol 2007;10(1):63–71. DOI: 10.1017/S1461145705006371

36. Carrington A.L., Calcutt N.A., Ettlinger C.B. et al. Effects of treatment with myo-inositol or its 1,2,6-trisphosphate (PP56) on nerve conduction in streptozotocin-diabetes. Eur J Pharmacol 1993;237(2–3):257–63. DOI: 10.1016/0014-2999(93)90277-o

37. Fux M., Levine J., Aviv A., Belmaker R.H. Inositol treatment of obsessive-compulsive disorder. Am J Psychiatry 1996;153(9):1219–21. DOI: 10.1176/ajp.153.9.1219

38. Palatnik A., Frolov K., Fux M., Benjamin J. Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder. J Clin Psychopharmacol 2001;21(3):335–9. DOI: 10.1097/00004714-200106000-00014

39. Levine J., Barak Y., Gonzalves M. et al. Double-blind, controlled trial of inositol treatment of depression. Am J Psychiatry 1995;152(5):792–4. DOI: 10.1176/ajp.152.5.792

40. Cavalli P., Tonni G., Grosso E., Poggiani C. Effects of inositol supplementation in a cohort of mothers at risk of producing an NTD pregnancy. Birth Defects Res A Clin Mol Teratol 2011;91(11):962–5. DOI: 10.1002/bdra.22853

41. Beemster P., Groenen P., Steegers-Theunissen R. Involvement of inositol in reproduction. Nutr Rev 2002;60(3):80–7. DOI: 10.1301/00296640260042748

42. Majerus P.W., Wilson D.B., Zhang C. et al. Expression of inositol 1,3,4-trisphosphate 5/6-kinase (ITPK1) and its role in neural tube defects. Adv Enzyme Regul 2010;50(1):365–72. DOI: 10.1016/j.advenzreg.2009.10.017

43. Wilson M.P., Hugge C., Bielinska M. et al. Neural tube defects in mice with reduced levels of inositol 1,3,4-trisphosphate 5/6-kinase. Proc Natl Acad Sci USA 2009;106(24):9831–5. DOI: 10.1073/pnas.0904172106

44. Cogram P., Tesh S., Tesh J. et al. D-chiro-inositol is more effective than myo-inositol in preventing folate-resistant mouse neural tube defects. Hum Reprod 2002;17(9):2451–8. DOI: 10.1093/humrep/17.9.2451

45. Калачева А.Г., Торшин И.Ю., Стельмашук Е.В. Нейропротекторное действие миоинозитола на клеточной модели глутаматного стресса как основа для профилактики нарушений внутриутробного развития головного мозга. Фармакокинетика и фармакодинамика 2018;3:9–20. DOI: 10.24411/2587-7836-2018-10018

46. Eriksson U.J., Wentzel P. Diabetic embryopathy. Methods Mol Biol 2012;889:425–36. DOI: 10.1007/978-1-61779-867-2_26

47. Akashi M., Akazawa S., Akazawa M. et al. Effects of insulin and myo-inositol on embryo growth and development during early organogenesis in streptozocin-induced diabetic rats. Diabetes 1991;40(12):1574–9. DOI: 10.2337/diab.40.12.1574

48. Khandelwal M., Reece E.A., Wu Y.K., Borenstein M. Dietary myo-inositol therapy in hyperglycemia-induced embryopathy. Teratology 1998;57(2):79–84. DOI: 10.1002/(SICI)1096-9926(199802)57:2<79::AID-TERA6>3.0.CO;2-1

49. Cogram P., Hynes A., Dunlevy L.P. et al. Specific isoforms of protein kinase C are essential for prevention of folate-resistant neural tube defects by inositol. Hum Mol Genet 2004;13(1):7–14. DOI: 10.1093/hmg/ddh003

50. Carlomagno G., Unfer V. Inositol safety: clinical evidences. Eur Rev Med Pharmacol Sci 2011;15(8):931–6. PMID: 21845803

51. Громова О.А., Торшин И.Ю., Уварова Е.В. и др. Систематический анализ биологических ролей и фармакологических свойств D-хироинозитола. Гинекология 2020;22(3):21–8. DOI: 10.26442/20795696.2020.3.200210

52. Fan C., Liang W., Wei M. et al. Effects of D-chiro-inositol on glucose metabolism in db/db mice and the associated underlying mechanisms. Front Pharmacol 2020;11:354. DOI: 10.3389/fphar.2020.00354

53. Ostlund R.E. Jr, McGill J.B., Herskowitz I. et al. D-chiro-inositol metabolism in diabetes mellitus. Proc Natl Acad Sci USA 1993;90(21):9988–92. DOI: 10.1073/pnas.90.21.9988

54. La Marca A., Grisendi V., Dondi G. et al. The menstrual cycle regularization following D-chiro-inositol treatment in PCOS women: a retrospective study. Gynecol Endocrinol 2015;31(1):52–6. DOI: 10.3109/09513590.2014.964201

55. Iuorno M.J., Jakubowicz D.J., Baillargeon J.P. et al. Effects of D-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract 2002;8(6):417–23. DOI: 10.4158/EP.8.6.417

56. Nestler J.E., Jakubowicz D.J., Reamer P. et al. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999;340(17):1314–20. DOI: 10.1056/NEJM199904293401703

57. Cheng F., Han L., Xiao Y. et al. D-chiro-inositol ameliorates high fat diet-induced hepatic steatosis and insulin resistance via PKCε-PI3K/AKT pathway. J Agric Food Chem 2019;67(21):5957–67. DOI: 10.1021/acs.jafc.9b01253

58. Zhao S.S., Li N.R., Zhao W.L. et al. D-chiro-inositol effectively attenuates cholestasis in bile duct ligated rats by improving bile acid secretion and attenuating oxidative stress. Acta Pharmacol Sin 2018;39(2):213–21. DOI: 10.1038/aps.2017.98

59. Zhao M., Song B., Pu J. et al. Electrical signals control wound healing through phosphatidylinositol-3-OH kinase-gamma and PTEN. Nature 2006;442(7101):457–60. DOI: 10.1038/nature04925

60. Guo M.F., Yu J.Z., Ma C.G. Mechanisms related to neuron injury and death in cerebral hypoxic ischaemia. Folia Neuropathol 2011;49(2):78–87. PMID: 21845535

61. Ганнушкина И.В., Шафранова В.П., Рясина Т.В. Функциональная ангиоархитектоника головного мозга. М.: Медицина, 1977. 240 с.

62. Hernández-Fonseca K., Cárdenas-Rodríguez N., Pedraza-Chaverri J., Massieu L. Calcium-dependent production of reactive oxygen species is involved in neuronal damage induced during glycolysis inhibition in cultured hippocampal neurons. J Neurosci Res 2008;86(8):1768–80. DOI: 10.1002/jnr.21634